Roche Acquires Chinese Antibody-Drug Conjugate Rights For $500M

(MENAFN- Swissinfo) The Swiss pharmaceutical company Roche has acquired the rights to a portfolio of antibody-drug conjugates (ADCs) developed by its Chinese competitor Hansoh Pharma, for $510 million (CHF420 million). Select your language

Generated with artificial intelligence. Listening: Roche acquires Chinese antibody-drug conjugate rights for $500m This content was published on October 19, 2026 - 14:50 1 minute Keystone-SDA

Italiano it Roche: mezzo miliardo per diritti su anticorpi coniugati cinesi Original Read more: Roche: mezzo miliardo per diritti su anticorpi coniugati c

The transaction consists of an initial instalment of $400 million, to be paid upon signing the contract, and a second instalment of $110 million, to be paid one year later.

The contract also provides for funding of $15 billion, subject to the achievement of development, regulatory or even commercial milestones, as well as commissions of an unspecified amount on any revenue, the Shanghai-based group stated in a press release issued today.

ADCs, or antibody-drug conjugates, are preparations that combine, amongst other things, an antibody and a chemotherapeutic molecule. Their purpose is to combat tumours.

More More Healthcare innovation Personalised cancer vaccines take a leap forward – can Swiss pharma catch up?

This content was published on Oct 14, 2026 Vaccines tailored to each patient's tumour look increasingly promising after positive melanoma trial results. But a Roche-backed vaccine stumbled, raising questions about where the approach can succeed.

Read more: Personalised cancer vaccines take a leap forward – can Swiss pharma catc

MENAFN19102026000210011054ID1111832925